3-[(2-Cyano-ethyl)-(4-{4-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-thiazol-2-yl]-piperidin-1-ylmethyl}-phenyl)-amino]-propionitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-[(2-Cyano-ethyl)-(4-{4-[4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-thiazol-2-yl]-piperidin-1-ylmethyl}-phenyl)-amino]-propionitrile
• 英文别名: 3-[N-(2-cyanoethyl)-4-[[4-[4-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,3-thiazol-2-yl]piperidin-1-yl]methyl]anilino]propanenitrile
• 化学式: C₃₅H₄₃N₅S
• 分子量: 565.8
• InChiKey: GIJMNRNXYGNVJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  41
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.51
• 拓扑面积：
  95.2
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Use of inhibitors of sirtuins and/or ampk for the preparation of a medicament for the treatment of polyalanine diseases.
  申请人：INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

  公开号：EP2014281A1

  公开（公告）日：2009-01-14

  This invention relates to the use of inhibitors of sirtuins and/or AMPK for the preparation of a medicament for the treatment of polyalanine diseases, in particular oculopharyngeal muscular dystrophy (OPMD). The invention also relates to methods of identifying compounds which can be useful for treating said diseases.

  本发明涉及利用sirtuins和/或AMPK的抑制剂制备治疗多氨酸疾病，特别是眼咽肌营养不良症（OPMD）的药物。本发明还涉及鉴定可用于治疗上述疾病的化合物的方法。
• [EN] USE OF INHIBITORS OF SIRTUINS AND/OR AMPK FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF POLYALANINE DISEASES.<br/>[FR] UTILISATION D'INHIBITEURS DE SIRTUINES ET/OU DE L'AMPK DANS LA PRÉPARATION D'UN MÉDICAMENT DESTINÉ AU TRAITEMENT DES MALADIES À POLYALANINE
  申请人：INST NAT SANTE RECH MED

  公开号：WO2008155390A2

  公开（公告）日：2008-12-24

  [EN] This invention relates to the use of inhibitors of sirtuins and/or AMPK for the preparation of a medicament for the treatment of polyalanine diseases, in particular oculopharyngeal musculardystrophy (OPMD). The invention also relates to methods of identifying compounds which can be useful for treating said diseases.
  [FR] L'invention porte sur l'utilisation d'inhibiteurs de sirtuines et/ou de l'AMPK dans la préparation d'un médicament destiné au traitement des maladies à polyalanine, en particulier la dystrophie musculaire oculopharyngée (DMOP). L'invention concerne également des procédés qui permettent d'identifier des composés pouvant être utilisés dans le traitement desdites maladies.